Patents by Inventor Claus Sundgreen

Claus Sundgreen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220016055
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Application
    Filed: July 27, 2021
    Publication date: January 20, 2022
    Inventors: Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Publication number: 20180185304
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 5, 2018
    Inventors: Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Publication number: 20170007557
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Application
    Filed: July 11, 2016
    Publication date: January 12, 2017
    Inventors: Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Patent number: 9387184
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: July 12, 2016
    Assignee: Saniona A/S
    Inventors: Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Publication number: 20160074344
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 17, 2016
    Inventors: Henrik Bjork Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Patent number: 9211271
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Grant
    Filed: February 14, 2013
    Date of Patent: December 15, 2015
    Assignee: SANIONA A/S
    Inventors: Henrik Björk Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jørgen Buus Lassen, Claus Sundgreen
  • Publication number: 20150025107
    Abstract: This invention relates to the use of pharmaceutical compositions comprising a therapeutically effective combination of Tesofensine and Metoprolol for preventing the cardiovascular side effects of Tesofensine, while leaving the robust inhibitory efficacy on food intake and body weight loss unaffected.
    Type: Application
    Filed: February 14, 2013
    Publication date: January 22, 2015
    Inventors: Henrik Björk Hansen, Morten Grunnet, Bo Hjorth Bentzen, Lars Hyveled-Nielsen, Jorgen Buus Lassen, Claus Sundgreen
  • Publication number: 20020147232
    Abstract: Novel pharmaceutical compositions comprising desglymidodrine or a pharmaceutically acceptable salt thereof as an active drug substance. Desglymidodrine is the active metabolite of the prodrug midodrine. The pharmaceutical composition may be presented in a suitable dosage form for oral, parenteral, mucosal, nasal, sublingual, buccal, topical, vaginal, rectalor ocular etc. administration. A pharmaceutical composition of the invention may be in the form of an immediate and/or modified release composition or it may be designed to release the active drug substance, desglymidodrine, in a relatively fast manner in order to enable a relatively fast onset of the therapeutic effect. The compositions have a suitable shelf-life, i.e. the desglymidodrine contained in the composition is not subject to a significant degradation under storage conditions normally acceptable for pharmaceuticals.
    Type: Application
    Filed: May 23, 2001
    Publication date: October 10, 2002
    Inventors: Claus Sundgreen, Ann Christina Schultz, Jimmy Hirschsprung Schlyter, Peder Mohr Olsen